Navigation Links
Aflac and the American Association for Cancer Research Unite to Issue Inaugural Aflac Career Development Award for Childhood Cancer Research
Date:4/29/2008

COLUMBUS, Ga., April 29 /PRNewswire/ -- Aflac and the American Association for Cancer Research (AACR) today announced the presentation of the first-ever AACR Career Development Award for Childhood Cancer Research, endowed by Aflac to aid in the fight to cure pediatric cancer. The award, which includes a two-year grant of $55,000 per year, was presented at AACR's Annual Meeting in San Diego, Calif., to Dr. Charles G. Mullighan, a hematologist and hematopathologist pursuing research in the area of molecular biology of acute leukemia. Dr. Mullighan conducts his research at the St. Jude Children's Research Hospital, a world-renowned cancer research facility located in Memphis, Tenn.

Dr. Mullighan was recommended for the Career Development Award by Dr. James R. Downing, scientific director and chairman of the Pathology Department at St. Jude. Dr. Downing noted that Dr. Mullighan as an outstanding candidate for having conducted a three-year pioneering study performing genomic profiling of pediatric acute leukemia.

"At Aflac, we believe that the road to conquering cancer is paved by the best and brightest of our young scientists," said Aflac Foundation President Kathelen Amos. "Aflac is proud to provide this endowment, which will enable young cancer research pioneers to continue their studies until we find a cure."

Praising Aflac's alliance, AACR Chief Executive Officer Margaret Foti, Ph.D., M.D. (h.c.), said, "For the past decade, Aflac has invested in helping young scientists and doctors get the training they need at our national meetings. Now, they have taken a giant step by supporting researchers in childhood cancers. Together, AACR and Aflac will make a difference in the lives of patients and their families."

In addition to the Career Development Award for Childhood Cancer Research, Aflac is a longtime supporter of the AACR's Scholar in Training Awards program, having contributed more than $1 million since 1997 and given more than 750 Scholar in Training Awards to deserving scientists. Aflac is also committed to enhancing the lives of children through excellence in patient care, research and education at the Aflac Cancer Center and Blood Disorders Service of Children's Healthcare of Atlanta. Children's, one of the top three pediatric healthcare systems in the country, is a not-for-profit organization that benefits from the generous philanthropic and volunteer support of the community. Visit http://www.aflaccancercenter.org or call 404-250-KIDS for more information.

About Aflac

For more than 50 years, Aflac products have given policyholders the opportunity to direct cash where it is needed most when a life-interrupting medical event causes financial challenges. Aflac is the number one provider of guaranteed-renewable insurance in the United States and the number one insurance company in terms of individual insurance policies in force in Japan. Our insurance products provide protection to more than 40 million people worldwide. Aflac has been included in Fortune magazine's listing of America's Most Admired Companies for seven years and in Fortune magazine's list of the 100 Best Companies to Work For in America for ten consecutive years. Aflac has also been recognized three times by both Fortune magazine's listing of the Top 50 Employers for Minorities and Working Mother magazine's listing of the 100 Best Companies for Working Mothers. Aflac Incorporated is a Fortune 500 company listed on the New York Stock Exchange under the symbol AFL. To find out more about Aflac, visit aflac.com.

About AACR

Founded in 1907, the AACR is a professional society of more than 22,000 laboratory and clinical scientists engaged in cancer research in the United States, Canada and more than 60 other countries. AACR's mission is to accelerate the prevention and cure of cancer through research, education, communication and advocacy. Its principal activities include the publication of five leading peer-reviewed scientific journals (Cancer Research, Clinical Cancer Research, Molecular Cancer Research, Cancer Epidemiology, Biomarkers & Prevention and Molecular Cancer Therapeutics).

About Dr. Charles Grenfell Mullighan

Dr. Charles Grenfell Mullighan, a native of South Australia, is a hematologist and hematopathologist pursuing research in the molecular biology of acute leukemia. He completed his hematology fellowship in Australia in January 2004 and has served as a Physician Scientist Postdoctoral Fellow in the laboratory of Dr. James Downing, Department of Pathology, St. Jude Children's Research Hospital.

(Logo: http://www.newscom.com/cgi-bin/prnh/20041202/CLTH019LOGO )

Media Contact: Analyst and Investment Contact:

Jon A. Sullivan Kenneth S. Janke Jr.

Aflac Incorporated Aflac Incorporated

706.763.4813 1.800.235.2667, Option 3;

jsullivan@aflac.com Fax: 706.324.6330

kjanke@aflac.com


'/>"/>
SOURCE Alfac Incorporated
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Aflac Honored with Corporate Citizenship Award
2. American Oriental Bioengineering to Report First Quarter 2008 Financial Results
3. FASgen, Inc. Presents Ovarian Cancer Efficacy and Toxicology Data to the American Association for Cancer Research
4. Telik Presents Preclinical Data at 99th Annual Meeting of the American Association for Cancer Research
5. SPO Medical Retains American Capital Ventures for Investor Relations Services
6. NexGenix Pharmaceuticals Presents Data on a Novel Small Molecule Inhibitor of Heat Shock Protein 90 (Hsp90) at the Annual Meeting of the American Association for Cancer Research (AACR); Scientific Advisory Board Chairman Tyler Jacks Named President-elect
7. Medarex Reports Phase 1/2 Clinical Data of MDX-060 in Lymphoma at American Association for Cancer Research Meeting
8. American Oriental Bioengineering and China Aoxing Pharmaceutical Enter Into Strategic Alliance
9. Paloma Pharmaceuticals to Present at the American Association for Cancer Research
10. Bionovo to Present Recent Findings of BN107 and BN108, Its Anticancer Agents, at the American Association of Cancer Research
11. Peregrine Pharmaceuticals Announces Four Upcoming Presentations at the American Association for Cancer Research 2008 Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... ... June 23, 2016 , ... Mosio, a leader ... “Clinical Trials Patient Recruitment and Retention Tips.” Partnering with experienced clinical research professionals, ... providing practical tips, tools, and strategies for clinical researchers. , “The landscape of ...
(Date:6/23/2016)... SPRING, Md. , June 23, 2016 A ... collected from the crime scene to track the criminal down. ... and the U.S. Food and Drug Administration (FDA) uses DNA ... Sound far-fetched? It,s not. The ... genome sequencing to support investigations of foodborne illnesses. Put as ...
(Date:6/23/2016)... June, 23, 2016  The Biodesign Challenge (BDC), a ... ways to harness living systems and biotechnology, announced its ... in New York City . ... students, showcased projects at MoMA,s Celeste Bartos Theater during ... , MoMA,s senior curator of architecture and design, and ...
(Date:6/23/2016)... ... 23, 2016 , ... In a new case report published today in STEM ... who developed lymphedema after being treated for breast cancer benefitted from an injection of ... dealing with this debilitating, frequent side effect of cancer treatment. , Lymphedema ...
Breaking Biology Technology:
(Date:6/9/2016)... an innovation leader in attendance control systems is proud to announce the introduction of ... make sure the right employees are actually signing in, and to even control the ... ... ... ...
(Date:6/2/2016)...   The Weather Company , an IBM Business (NYSE: ... capability in which consumers will be able to interact with ... via voice or text and receive relevant information about the ... Marketers have long sought an advertising solution that can create ... relevant and valuable; and can scale across millions of interactions ...
(Date:5/16/2016)... , May 16, 2016   EyeLock LLC ... today announced the opening of an IoT Center of ... strengthen and expand the development of embedded iris biometric ... unprecedented level of convenience and security with unmatched biometric ... one,s identity aside from DNA. EyeLock,s platform uses video ...
Breaking Biology News(10 mins):